Hemostemix Announces First Patient Treated in Stem Cell Trial for Critical Limb Ischemia

Hemostemix Inc. (TSX VENTURE:HEM) announced on 5/3/18 that it has treated its first patient under its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”).  The first patient was treated at the Vancouver Coastal Health Research Institute (“VCHRI”), a world leader in translational health research for new therapies, led by the principal investigator, Dr. York N. Hsiang, MB ChB MHSc FRCSC.